Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias
Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up
Objective: To follow the clinical status of 4 PD patients transplanted with NTCELL out to 81-130 weeks. Background: NTCELL comprises neonatal porcine choroid plexus cells…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies
Objective: Evaluate the onset and stability of the therapeutic effect of opicapone (OPC) compared to placebo in patients with Parkinson's disease and motor fluctuations over…Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression
Objective: Evaluate the efficacy of opicapone (OPC) in fluctuating Parkinson's disease patients at different stages of symptom progression over a 14-15 week treatment period. Background:…Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone
Objective: Evaluate the effects of opicapone (OPC) on the activities of daily living and motor scores of the UPDRS in fluctuating Parkinson's disease patients. Background:…Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment
Objective: Evaluate the impulse control disorders reported as adverse events in phase III studies with opicapone (OPC) in fluctuating Parkinson's disease patients. Background: Impulse control…Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease
Objective: The aim of this study was to assess the use of cortical oscillations as translational biomarkers for drug development for the motor symptoms of…Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry
Objective: To evaluate baseline predictors and longitudinal impact of anticholinergics use in Parkinson's disease (PD). Background: Anticholinergics have beneficial effect on tremor in PD but…Experience with utilization of rytary in the clinical setting
Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.